학술논문
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Document Type
Academic Journal
Author
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. paolo.ascierto@gmail.com.; Agarwala SS; Temple University School of Medicine, Philadelphia, PA, USA.; Warner AB; Stanford University School of Medicine, Stanford, CA, USA.; Ernstoff MS; ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Cancer Therapy and Diagnosis Division, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.; Fox BA; Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.; Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA.; Galon J; INSERM, Laboratory of Integrative Cancer Immunology, 75006, Paris, France.; Centre de Recherche Des Cordeliers, Sorbonne Université, Université de Paris, Paris, France.; Equipe Labellisée Ligue Contre le Cancer, Paris, France.; Garbe C; Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.; Gastman BR; Department of Surgery, School of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.; Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Kalinski P; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Krogsgaard M; Laura and Isaac Perlmutter Cancer Center and Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA.; Leidner RS; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.; Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Menzies AM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.; Michielin O; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.; Poulikakos PI; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Weber JS; Laura and Isaac Perlmutter Cancer Center, a NCI-Funded Comprehensive Cancer Center, NYU School of Medicine, New York, NY, USA.; Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy.; Osman I; Rudolf L, Baer, New York University Langone Medical Center, New York, NY, USA.; Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Thurin M; Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institute of Health (NIH), Bethesda, MD, USA.
Source
Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE
Subject
Language
English
Abstract
Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen-4 (CTLA-4). Combinations of these checkpoint therapies with other agents are now being explored to improve outcomes and enhance benefit-risk profiles of treatment. Alternative inhibitory receptors have been identified that may be targeted for anti-tumor immune therapy, such as lymphocyte-activation gene-3 (LAG-3), as have several potential target oncogenes for molecularly targeted therapy, such as tyrosine kinase inhibitors. Unfortunately, many patients still progress and acquire resistance to immunotherapy and molecularly targeted therapies. To bypass resistance, combination treatment with immunotherapies and single or multiple TKIs have been shown to improve prognosis compared to monotherapy. The number of new combinations treatment under development for melanoma provides options for the number of patients to achieve a therapeutic benefit. Many diagnostic and prognostic assays have begun to show clinical applicability providing additional tools to optimize and individualize treatments. However, the question on the optimal algorithm of first- and later-line therapies and the search for biomarkers to guide these decisions are still under investigation. This year, the Melanoma Bridge Congress (Dec 1 st -3rd, 2022, Naples, Italy) addressed the latest advances in melanoma research, focusing on themes of paramount importance for melanoma prevention, diagnosis and treatment. This included sessions dedicated to systems biology on immunotherapy, immunogenicity and gene expression profiling, biomarkers, and combination treatment strategies.
(© 2023. The Author(s).)
(© 2023. The Author(s).)